Neurocrine Biosciences Announces U.S. FDA Approval of INGREZZA® SPRINKLE (valbenazine) Capsules
![img: Featured](/wp-content/themes/neurocrine/assets/img/feature-5.jpg)
SAN DIEGO , April 30, 2024 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration has approved INGREZZA ® SPRINKLE (valbenazine) capsules, a new oral granules formulation of INGREZZA ® (valbenazine) capsules prescribed for the treatment of